Showing results (1501-1510 of 2,038) with videos related to
Sort By:
Pageof 204
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2015
The Landscape of Prognostic Outlier Genes in High-Risk Prostate CancerShuang G Zhao, Joseph R Evans, Vishal Kothari, et al.Cancer Research|April 7, 2019
Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate CancerShangze Li, Ka-Wing Fong, Galina Gritsina, et al.JNCI Cancer Spectrum|October 9, 2025
Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancerWilliam S Chen, Abuzar Moradi Tuchayi, Ali Sabbagh, et al.International Journal of Radiation Oncology, Biology, Physics|June 17, 2020
Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate CancerNeil R Parikh, Eric M Chang, Nicholas G Nickols, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2015
Integrative molecular profiling of routine clinical prostate cancer specimensC S Grasso, A K Cani, D H Hovelson, et al.ESMO Open|November 26, 2025
Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib studyS Kuemmel, K H Jung, L Andrade, et al.European Journal of Nuclear Medicine and Molecular Imaging|August 19, 2020
False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trialWolfgang P Fendler, Jeremie Calais, Matthias Eiber, et al.Cancer|July 20, 2016
National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?Brandon A Mahal, Yu-Wei Chen, Vinayak Muralidhar, et al.Nature|April 25, 2014
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancerIrfan A Asangani, Vijaya L Dommeti, Xiaoju Wang, et al.Cancer Research|October 23, 2022
Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2Patrick C O'Leary, Huadong Chen, Yagmur U Doruk, et al.Pageof 204